New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanadelumab 150 mg/ml;   - solution for injection - 300 mg/2ml - active: lanadelumab 150 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate dihydrate histidine polysorbate 80 sodium chloride water for injection - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angiodema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years or older.

Canada - English - Health Canada

takeda canada inc - lanadelumab - solution - 300mg - lanadelumab 300mg - complement inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - lanadelumab, quantity: 300 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; histidine; sodium chloride - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older.